P172 CURCUMIN AND RESVERATROL REDUCE LIPOPOLYSACCHARIDE MEDIATED GLYCOSAMINOGLYCAN RELEASE IN AN EXPLANT MODEL OF CANINE ARTICULAR CARTILAGE  by Williamson, S.M. et al.
S102 Poster Presentations
P172
CURCUMIN AND RESVERATROL REDUCE
LIPOPOLYSACCHARIDE MEDIATED
GLYCOSAMINOGLYCAN RELEASE IN AN EXPLANT
MODEL OF CANINE ARTICULAR CARTILAGE
S.M. Williamson1, A. Mobasheri2, A. Vaughan-Thomas1,
N.J. Thompson1, M. Shakibaei3
1Faculty of Veterinary Science, University of Liverpool,
Liverpool, United Kingdom, 2Division of Veterinary Medicine,
School of Veterinary Science and Medicine, University of
Nottingham, Sutton Bonington Campus, Loughborough, United
Kingdom, 3Institute of Anatomy, Faculty of Medicine, Ludwing
Maximilians University, Munich, Germany
Purpose: The aim of this study was to determine the effects
of co-treatment with the dietary phytochemical curcumin (de-
rived from Curcuma longa) and the polyphenolic phytoalexin
stilbene resveratrol (found in red grapes, red wine, peanuts and
some berries) on glycosaminoglycan (GAG) release from ex-
plants of canine articular cartilage challenged with lipopolysac-
charide (LPS).
Methods: Samples of canine articular cartilage were harvested
from the stifle joints and used to establish an ex vivo ex-
plant model. The explants were incubated in serum-free DMEM
medium containing antibiotics and challenged with LPS at con-
centrations of 0.25, 0.5, 1.25, 2.5 and 5 μg/ml thus creating a
model of joint inflammation. LPS stimulated samples and con-
trols were co-treated with either curcumin or resveratrol, both at
2.5 μM for a period of 5 days. The tissue culture medium and
the papain digested cartilage explants were analysed for GAG
content by the dimethylmethylene blue (DMMB) assay. LPS me-
diated GAG release into the culture medium was then expressed
as a percentage of the total GAG present in the explants prior to
experimentation.
Results: The DMMB assay confirmed the degradative effect of
LPS on canine cartilage explants. Challenge with LPS signifi-
cantly increased GAG release into the culture medium; increas-
ing the concentration of LPS increased GAG release in a dose
dependent manner. Co-treatment with 2.5 μM curcumin and 2.5
μM resveratrol antagonized the degradative actions of LPS and
decreased GAG release from the explants. GraphPad InStat soft-
ware was used for statistical analysis of data obtained with LPS
at 0.25 μg/ml (One-way ANOVA, Student-Newman-Keuls test).
There was a significant difference in GAG release between con-
trol and LPS stimulated samples (P<0.001). There was a marked
difference between the LPS stimulated samples with and without
2.5 μM resveratrol (P<0.001). Statistically significant differences
were also noted between the LPS stimulated samples with and
without 2.5 μM curcumin (P<0.001). The results are summarized
in Figure 1.
Fig. 1
Conclusions: We have shown for the first time that micromolar
concentrations of curcumin and resveratrol down-regulate the
catabolic and degradative effects of LPS, particularly its effects
on GAG release in explant cultures of canine articular carti-
lage. Therefore dietary phytochemicals and phytoalexin stilbenes
such as curcumin and resveratrol may have nutritional potential
as naturally occurring anti-inflammatory agents for treating os-
teoarthritis (OA). Future experiments will investigate the effects
of these compounds on the activity of inflammatory enzymes in-
cluding matrix metalloproteinases (MMPs) and cyclooxygenase 2
(COX-2) that modulate the catabolic status of articular cartilage.
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Purpose: The primary aim of this study was to investigate, using
an experimental rat model of osteoarthritis(OA), the effect of a se-
lective p38 mitogen activatedprotein kinase inhibitor,SB203580,
on the development of structural changes. Additional aims were
to assess the effects of the inhibitor on levels of matrixmetallopro-
teinase 3 (MMP-3) and MMP-13(collagenase 3) in OA cartilage
and to explore the relation between the MMP-3,13 expression
and the severity of OA.
Methods: OA was induced in 40 SD rats by anterior cruciate
ligament transection (ACLT). After surgical, rats with OA were
randomly divided into A_D groups: Rats of group A received 0.1
ml intra-articular injection of SB203580 at high oncentration of
100um/L. Each treatment started immediately after surgery, once
a week; those in group B were treated under the same condition
using SB203580 with low oncentration of 10um/L and those in
group C received 0.1ml of intra-articular 0.9% Sodium Chloride
injection, animals of group D were not injected as controls
after ACLT. The animals were killed 8 weeks after surgery.
Macroscopic and histological studies were performed on the
cartilage. The levels of MMP-3, 13 in OA cartilage chondrocytes
were evaluated by immunohistochemistry and western blotting.
Results: All ACLT knees demonstrated osteoarthritic changes.
Cartilage degradation in the control group was significantly sev-
erer than that in the experimental group both on the macroscopic
grading scale and on Mankin’s grading scale (P <0.05). Im-
munohistochemical study showed that in the experimental group
MMP-3, 13 was predominantly expressed in the superficial and
upper intermediate layers of cartilage, and the amount of MMP-3,
13 in the experimental group was also lower than that in con-
trol group(P <0.05). In western blotting, the amount of MMP-3,
13 was reduced by the treatment of the inhibitor. The protein
levels of MMP-3 and MMP-13 in cartilage of inhibitor injection
groups were significantly lower than those of Sodium Chloride
group and untreated group. There was no significant difference
in MMP-3 and MMP-13 expression between the different con-
centration inhibitor injection groups. No significant difference in
MMP-3 and MMP-13 expression in cartilage was found between
Sodium Chloride group and control group.
Conclusions: This study demonstrates that, in vivo, SB203580,
a selective inhibitor of p38MAPK, can partially decrease the de-
velopment of some of the structural changes in the early phases
of experimental OA and significantly reduces the severity of car-
tilage degradation. This effect was associated with a reduction in
the level of MMP-3,13 in OA cartilage, which probably explains
the action of the drug and thus may be a potential drug for the
treatment of OA.
